gefitinib has been researched along with berberine in 3 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (berberine) | Trials (berberine) | Recent Studies (post-2010) (berberine) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 4,106 | 102 | 2,791 |
| Protein | Taxonomy | gefitinib (IC50) | berberine (IC50) |
|---|---|---|---|
| Acetylcholinesterase | Electrophorus electricus (electric eel) | 0.7827 | |
| Lysine-specific histone demethylase 1A | Homo sapiens (human) | 6.97 | |
| Cholinesterase | Homo sapiens (human) | 1.09 | |
| Acetylcholinesterase | Homo sapiens (human) | 0.4 | |
| Aldo-keto reductase family 1 member C3 | Homo sapiens (human) | 4.99 | |
| Aldo-keto reductase family 1 member C2 | Homo sapiens (human) | 6.71 | |
| Cholinesterase | Equus caballus (horse) | 9.4 | |
| Cytochrome P450 1B1 | Homo sapiens (human) | 0.9747 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, Y; Chai, Y; Chen, X; Lv, D; Zhang, J; Zhu, Z | 1 |
| Fan, XX; Fu, J; He, JX; Huang, J; Jiang, ZB; Kam, RK; Leung, EL; Liu, L; Liu, ZQ; Lu, LL; Luo, LX; Wei, CL; Wu, JL; Xiao, DK; Xie, Y; Yao, XJ; Yuan, ZW; Zheng, YF; Zhou, YL | 1 |
| Chai, X; Hann, SS; Li, J; Ma, C; Tang, Q; Tang, X; Wu, J; Xie, J; Yang, XB; Zheng, F | 1 |
3 other study(ies) available for gefitinib and berberine
| Article | Year |
|---|---|
Comprehensive two-dimensional HepG2/cell membrane chromatography/monolithic column/time-of-flight mass spectrometry system for screening anti-tumor components from herbal medicines.
Topics: Alkaloids; Antineoplastic Agents; Berberine; Berberine Alkaloids; Cell Proliferation; Chromatography, Liquid; Drugs, Chinese Herbal; ErbB Receptors; Gefitinib; Hep G2 Cells; Humans; Mass Spectrometry; Matrines; Quinazolines; Quinolizines; Reproducibility of Results | 2012 |
Suppression of Lipogenesis via Reactive Oxygen Species-AMPK Signaling for Treating Malignant and Proliferative Diseases.
Topics: AMP-Activated Protein Kinases; Arthritis, Rheumatoid; Berberine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fibroblasts; Gefitinib; Gene Expression Regulation; Humans; Lipogenesis; Oxidation-Reduction; Quinazolines; Reactive Oxygen Species; Signal Transduction; Sterol Regulatory Element Binding Protein 1; Synovial Fluid | 2018 |
Novel regulation of miR-34a-5p and HOTAIR by the combination of berberine and gefitinib leading to inhibition of EMT in human lung cancer.
Topics: Animals; Apoptosis; Berberine; Cell Line, Tumor; Cell Movement; Cell Survival; Epithelial-Mesenchymal Transition; Female; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; MicroRNAs; RNA, Long Noncoding | 2020 |